ATE400275T1 - Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus - Google Patents
Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonusInfo
- Publication number
- ATE400275T1 ATE400275T1 AT03791769T AT03791769T ATE400275T1 AT E400275 T1 ATE400275 T1 AT E400275T1 AT 03791769 T AT03791769 T AT 03791769T AT 03791769 T AT03791769 T AT 03791769T AT E400275 T1 ATE400275 T1 AT E400275T1
- Authority
- AT
- Austria
- Prior art keywords
- adenosine
- worst
- treatment
- receptor antagonists
- legs syndrome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40695502P | 2002-08-30 | 2002-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE400275T1 true ATE400275T1 (de) | 2008-07-15 |
Family
ID=31978389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03791769T ATE400275T1 (de) | 2002-08-30 | 2003-08-27 | Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus |
Country Status (16)
Country | Link |
---|---|
US (1) | US7759355B2 (de) |
EP (1) | EP1534289B2 (de) |
JP (1) | JP4498140B2 (de) |
KR (1) | KR20050058468A (de) |
CN (1) | CN1671390A (de) |
AR (1) | AR041116A1 (de) |
AT (1) | ATE400275T1 (de) |
AU (1) | AU2003262860A1 (de) |
BR (1) | BR0313503A (de) |
CA (1) | CA2496920A1 (de) |
DE (1) | DE60322067D1 (de) |
EA (1) | EA008339B1 (de) |
ES (1) | ES2310258T5 (de) |
MX (1) | MXPA05001461A (de) |
TW (1) | TW200410698A (de) |
WO (1) | WO2004019949A1 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2942082B1 (de) * | 2002-01-28 | 2019-03-06 | Kyowa Hakko Kogyo Co., Ltd | A2a rezeptor antagonisten zur verwendung in der behandlung von bewegungsstörungen |
US20060106040A1 (en) * | 2002-12-19 | 2006-05-18 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
CN100415217C (zh) * | 2002-12-19 | 2008-09-03 | 先灵公司 | 腺苷A2a受体拮抗剂的应用 |
WO2005094885A1 (ja) * | 2004-03-30 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | 慢性筋骨格痛を呈する疾患の予防および/または治療剤 |
ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
EP2445501A2 (de) * | 2009-06-26 | 2012-05-02 | Ferring B.V. | Verwendung von quinagolid bei der behandlung von endometriose, schmerz und krebs |
RU2480469C1 (ru) * | 2012-02-03 | 2013-04-27 | Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") | Замещенные 1,3-диэтил-8-винил-7-метил-3,7-дигидро-пурин-2,6-дионы-антагонисты аденозинового a2a рецептора и их применение |
EP3698793A1 (de) | 2014-01-29 | 2020-08-26 | Vyome Therapeutics Limited | Besifloxacin zur behandlung von resistenter akne |
WO2022167778A1 (en) | 2021-02-02 | 2022-08-11 | Haiku Therapeutics Ltd | Ebselen as adenosine receptor modulator |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5484920A (en) * | 1992-04-08 | 1996-01-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for Parkinson's disease |
AU3716997A (en) | 1996-07-17 | 1998-02-09 | Merck & Co., Inc. | Alteration of circadian rhythmicity with a tachykinin antagonist |
US6001861A (en) | 1998-01-16 | 1999-12-14 | Pharmacia & Upjohn Company | Use of pramipexole in the treatment of restless legs syndrome |
SE509618C2 (sv) | 1997-03-06 | 1999-02-15 | Goeran Blomqvist | Farmaceutisk komposition för behandling av s k restless legs |
US6114326A (en) | 1998-03-27 | 2000-09-05 | Pharmacia & Upjohn Company | Use of cabergoline in the treatment of restless legs syndrome |
US20010029262A1 (en) | 1998-06-29 | 2001-10-11 | Sethi Kapil Dev | Method of treatment or prophylaxis |
US5945424A (en) | 1998-07-31 | 1999-08-31 | G & H Associates, Inc. | Treatment of periodic limb movement syndrome |
US6346283B1 (en) | 1999-03-26 | 2002-02-12 | Ancile Pharmaceuticals | Use of valeriana for the treatment of restless leg syndrome and related disorders |
DE19938825A1 (de) | 1999-08-19 | 2001-04-26 | Boehringer Ingelheim Pharma | Wirkstoffkombination mit Clonidin |
US6281207B1 (en) | 1999-09-15 | 2001-08-28 | Reed Richter | Treatment of movement disorders by administration of mirtazapine |
US20010034320A1 (en) | 2000-01-18 | 2001-10-25 | Hans-Michael Brecht | NK1-receptor antagonists for treating restless legs syndrome |
JP2003523405A (ja) * | 2000-02-22 | 2003-08-05 | セレジー カナダ インコーポレイテッド | 睡眠改善のための方法および組成物 |
US6258814B1 (en) | 2000-10-13 | 2001-07-10 | Schering Corporation | Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep |
EP2942082B1 (de) | 2002-01-28 | 2019-03-06 | Kyowa Hakko Kogyo Co., Ltd | A2a rezeptor antagonisten zur verwendung in der behandlung von bewegungsstörungen |
US20080176873A1 (en) * | 2004-11-10 | 2008-07-24 | Trinity Laboratories, Inc. | Novel Pharmaceutical Compositions for Treating Acquired Chronic Pain and Associated Dysphoria |
-
2003
- 2003-08-27 DE DE60322067T patent/DE60322067D1/de not_active Expired - Lifetime
- 2003-08-27 WO PCT/US2003/026644 patent/WO2004019949A1/en active Application Filing
- 2003-08-27 AU AU2003262860A patent/AU2003262860A1/en not_active Abandoned
- 2003-08-27 EA EA200500427A patent/EA008339B1/ru unknown
- 2003-08-27 US US10/523,603 patent/US7759355B2/en not_active Expired - Fee Related
- 2003-08-27 EP EP03791769A patent/EP1534289B2/de not_active Expired - Lifetime
- 2003-08-27 CA CA002496920A patent/CA2496920A1/en not_active Abandoned
- 2003-08-27 BR BR0313503-9A patent/BR0313503A/pt not_active IP Right Cessation
- 2003-08-27 MX MXPA05001461A patent/MXPA05001461A/es unknown
- 2003-08-27 JP JP2004533000A patent/JP4498140B2/ja not_active Expired - Fee Related
- 2003-08-27 AT AT03791769T patent/ATE400275T1/de not_active IP Right Cessation
- 2003-08-27 ES ES03791769T patent/ES2310258T5/es not_active Expired - Lifetime
- 2003-08-27 KR KR1020057003062A patent/KR20050058468A/ko not_active Application Discontinuation
- 2003-08-27 CN CNA038180006A patent/CN1671390A/zh active Pending
- 2003-08-29 TW TW092123858A patent/TW200410698A/zh unknown
- 2003-09-01 AR ARP030103162A patent/AR041116A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP1534289B1 (de) | 2008-07-09 |
KR20050058468A (ko) | 2005-06-16 |
WO2004019949A1 (en) | 2004-03-11 |
EP1534289B2 (de) | 2012-02-22 |
TW200410698A (en) | 2004-07-01 |
ES2310258T5 (es) | 2012-05-31 |
EA200500427A1 (ru) | 2005-08-25 |
US7759355B2 (en) | 2010-07-20 |
CN1671390A (zh) | 2005-09-21 |
BR0313503A (pt) | 2005-06-21 |
EA008339B1 (ru) | 2007-04-27 |
JP4498140B2 (ja) | 2010-07-07 |
DE60322067D1 (de) | 2008-08-21 |
AR041116A1 (es) | 2005-05-04 |
US20050245545A1 (en) | 2005-11-03 |
EP1534289A1 (de) | 2005-06-01 |
MXPA05001461A (es) | 2005-06-03 |
ES2310258T3 (es) | 2009-01-01 |
JP2005539050A (ja) | 2005-12-22 |
CA2496920A1 (en) | 2004-03-11 |
AU2003262860A1 (en) | 2004-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20044345L (no) | NE- og 5-HT reopptakinhibitorer for behandling av viscerale smertesyndromer | |
IS8119A (is) | Þétt N-heteróhringlaga efnasambönd og notkun þeirra sem CRF viðtakamótlyfja | |
ATE490775T1 (de) | Verwendung von a2a rezeptor-antagonisten zur behandlung des extrapyramidalen syndroms | |
LU92684I2 (fr) | Fidaxomicine ou son sel pharmaceutiquement acceptable | |
DE60305374D1 (de) | Insassenbeinschutzvorrichtung | |
DK1583542T3 (da) | Sammensætninger og fremgangsmåder til antiviral kombinationsterapi | |
ITVR20020006A1 (it) | Ortesi per ginocchio ostoartritico | |
NO20055204D0 (no) | Derivater av piperidinyl- og pipemzinylalkylkarbamater, fremgangsmater for fremstilling derav og anvendelse av de samme i terapi | |
NO20052894D0 (no) | 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte | |
IS7874A (is) | Ímídasókínólínafleiður sem adenósín A3 viðtakabindlar | |
IL180371A0 (en) | Method of treating sjogren's syndrome | |
PL374832A1 (en) | Novel substituted benzimidazole dosage forms and method of using same | |
DE60324911D1 (de) | Bestimmung der atrio-ventrikulären verzögerung | |
DE50308694D1 (de) | Bestrahlungsger t | |
IS8526A (is) | CRF viðtakamótlyf og aðferðir tengdar þeim | |
HK1091141A1 (en) | Compositions and methods for restoring sensitivity to treatment with her2 antagonists | |
AP2005003200A0 (en) | Piperdine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1. | |
ATE400275T1 (de) | Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus | |
NO20016246L (no) | Selektiv iGluR5 reseptorantagonist for behandling av migrene | |
ATE382331T1 (de) | Mehrschichtiges transmucosales therapeutisches system | |
ZA200802552B (en) | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders | |
ZA200803236B (en) | Adenosine A2a receptor antagonists for the treatment of Extra-Pyramidal syndrome and other movement disorders | |
DE60325855D1 (de) | Rifampicin zur Behandlung der Angiogenese | |
DE60127712D1 (de) | Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen | |
NO20052012L (no) | Indoler nyttige for behadling av androgen-reseptor relaterte sykdommer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |